BACKGROUND: Survival with left ventricular assist device (LVAD) therapy is dependent on appropriate patient selection. The HeartMate II risk score (HMRS) was recently derived and validated to predict 90-day mortality in clinical trial patients with continuous-flow LVADs. The aim of this study was to test HMRS validity in predicting survival at our institution. METHODS: We performed a retrospective analysis of patients implanted with HeartMate II (HMII; Thoratec, Pleasanton, CA) LVADs from March 31, 2004 to September 20, 2012 at the Columbia University Medical Center (CUMC). Patients were stratified according to HMRS profiles (HMRS Low < 1.58, 1.58 ≤ HMRS Medium ≤ 2.48, HMRS High > 2.48) calculated using age, albumin, creatinine, international normalized ratio (INR) and center volume. Outcome was defined as survival at 90 days after device implantation. RESULTS: HeartMate II LVADs were implanted in 205 patients. Pre-operative data from 201 patients were categorized into HMRS Low (n = 101; 1.04 [0.64 to 1.31]), HMRS Medium (n = 73; 1.98 [1.78 to 2.25]) and HMRS High (n = 27, 3.07 [2.70 to 3.43]) (p < 0.0001). Kaplan-Meier survival estimates at 90 days (HMRS Low 91.0 ± 2.9%, HMRS Medium 91.7 ± 3.2%, HMRS High 88.7 ± 6.1%) and at 1 year (HMRS Low 85.5 ± 3.8%, HMRS Medium 79.3 ± 5.5%, HMRS High 82.4 ± 8.4%) after LVAD implantation were not statistically different (p = 0.43). Prediction of 90-day mortality by receiver operating characteristic was poor (AUC = 0.56). CONCLUSION: HMRS stratification poorly discriminates 90-day mortality after HMII LVAD implantation at our institution. Its generalizability as a universal prognostic score may be limited.
BACKGROUND: Survival with left ventricular assist device (LVAD) therapy is dependent on appropriate patient selection. The HeartMate II risk score (HMRS) was recently derived and validated to predict 90-day mortality in clinical trial patients with continuous-flow LVADs. The aim of this study was to test HMRS validity in predicting survival at our institution. METHODS: We performed a retrospective analysis of patients implanted with HeartMate II (HMII; Thoratec, Pleasanton, CA) LVADs from March 31, 2004 to September 20, 2012 at the Columbia University Medical Center (CUMC). Patients were stratified according to HMRS profiles (HMRS Low < 1.58, 1.58 ≤ HMRS Medium ≤ 2.48, HMRS High > 2.48) calculated using age, albumin, creatinine, international normalized ratio (INR) and center volume. Outcome was defined as survival at 90 days after device implantation. RESULTS: HeartMate II LVADs were implanted in 205 patients. Pre-operative data from 201 patients were categorized into HMRS Low (n = 101; 1.04 [0.64 to 1.31]), HMRS Medium (n = 73; 1.98 [1.78 to 2.25]) and HMRS High (n = 27, 3.07 [2.70 to 3.43]) (p < 0.0001). Kaplan-Meier survival estimates at 90 days (HMRS Low 91.0 ± 2.9%, HMRS Medium 91.7 ± 3.2%, HMRS High 88.7 ± 6.1%) and at 1 year (HMRS Low 85.5 ± 3.8%, HMRS Medium 79.3 ± 5.5%, HMRS High 82.4 ± 8.4%) after LVAD implantation were not statistically different (p = 0.43). Prediction of 90-day mortality by receiver operating characteristic was poor (AUC = 0.56). CONCLUSION: HMRS stratification poorly discriminates 90-day mortality after HMII LVAD implantation at our institution. Its generalizability as a universal prognostic score may be limited.
Authors: Jennifer Cowger; Palak Shah; John Stulak; Simon Maltais; Keith D Aaronson; James K Kirklin; Francis D Pagani; Christopher Salerno Journal: J Heart Lung Transplant Date: 2015-11-06 Impact factor: 10.247
Authors: Lauren K Truby; Lakshmi Sridharan; Raul J Flores; A Reshad Garan; Douglas Jennings; Melana Yuzefpolskaya; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Paolo C Colombo; Veli K Topkara Journal: ASAIO J Date: 2019 Mar/Apr Impact factor: 2.872
Authors: Manreet K Kanwar; Lisa C Lohmueller; Robert L Kormos; Jeffrey J Teuteberg; Joseph G Rogers; JoAnn Lindenfeld; Stephen H Bailey; Colleen K McIlvennan; Raymond Benza; Srinivas Murali; James Antaki Journal: JACC Heart Fail Date: 2018-08-08 Impact factor: 12.035
Authors: Manreet K Kanwar; Lisa C Lohmueller; Robert L Kormos; Natasha A Loghmanpour; Raymond L Benza; Robert J Mentz; Stephen H Bailey; Srinivas Murali; James F Antaki Journal: ASAIO J Date: 2017 May/Jun Impact factor: 2.872
Authors: Natasha A Loghmanpour; Manreet K Kanwar; Marek J Druzdzel; Raymond L Benza; Srinivas Murali; James F Antaki Journal: ASAIO J Date: 2015 May-Jun Impact factor: 2.872
Authors: Luigi Adamo; Michael Nassif; Anjan Tibrewala; Eric Novak; Justin Vader; Scott C Silvestry; Akinobu Itoh; Gregory A Ewald; Douglas L Mann; Shane J LaRue Journal: JACC Heart Fail Date: 2015-03-11 Impact factor: 12.035
Authors: Byron C Jaeger; Ryan Cantor; Venkata Sthanam; Rongbing Xie; James K Kirklin; Ramaraju Rudraraju Journal: Circ Cardiovasc Qual Outcomes Date: 2021-09-14
Authors: Kelsey M Flint; John A Spertus; Fengming Tang; Philip Jones; Timothy J Fendler; Larry A Allen Journal: BMC Cardiovasc Disord Date: 2017-03-14 Impact factor: 2.298